Anjarium Biosciences Raises CHF 55.5 Million Series A Financing

Through its innovative approach Anjarium has the potential to deliver more predictable, lasting, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. Further, this new class of gene therapy provides the opportunity to address key shortcomings of current viral gene therapy development by creating medicines with reduced immunogenicity, increased drug payload capacity, enhanced targeted delivery, and individualized multiple dosing. The Company’s unique platform combines proprietary DNA-based gene vectors - vehicles for delivering foreign DNA into recipient cells -, natural and synthetic nanoparticle delivery modalities, including its novel Hybridosome technology, and cost-efficient, scalable manufacturing solutions.

The Schlieren-based company was founded in 2016 and up until now only known to insiders. Now it has announced one of the largest Series A financing rounds ever generating CHF55.5 million. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). The proceeds from the Series A financing will enable Anjarium to expand its team, advance its ground-breaking platform and progress several therapeutic pipeline programs towards clinical development.

Bali Muralidhar, Managing Partner at Abingworth, said: “Anjarium has an exciting and versatile technology that presents a broad opportunity to enhance and extend the reach of gene therapy. We look forward to supporting the team to develop its technology and translate its innovative science into life-changing products.” Bram Vanparys, Partner at Gimv, added: “We are very excited to support Anjarium as its groundbreaking science, platform and manufacturing setup holds very high potential to change the way we approach gene therapy today – with the possibility to deliver products with much better outcomes and durability.” In conjunction with Anjarium’s Series A financing, Bali Muralidhar of Abingworth, Bram Vanparys of Gimv and Dina Chaya of Omega Funds will join the company's Board of Directors.

(Press release / SK)